CS
LENZ

Candriam SCA’s LENZ Therapeutics LENZ Stock Holding History

Candriam SCA’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-374,932
Closed -$6M – 732
2025
Q4 		$6M Buy
374,932
+145,990
+64% +$4.26M 0.03% 356
2025
Q3 		$10.7M Buy
228,942
+57,668
+34% +$2.12M 0.06% 264
2025
Q2 		$5.02M Buy
+171,274
New +$4.66M 0.03% 348

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Candriam SCA's LENZ Position: Q1 2026 in Review

Candriam SCA sold out of LENZ Therapeutics (LENZ) in Q1 2026, closing a stake of 374,932 shares — an estimated $6M sold.

Candriam SCA first reported a position in LENZ in Q2 2025 and held it in 3 quarters. The position peaked at $10.7M in Q3 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

  • Candriam SCA reported no remaining LENZ Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Candriam SCA sold 374,932 LENZ Therapeutics shares in Q1 2026, an estimated $6M.
  • Candriam SCA first reported a position in LENZ Therapeutics in Q2 2025 and held it in 3 quarters.
  • Candriam SCA's LENZ Therapeutics position peaked at $10.7M in Q3 2025.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Candriam SCA's 13F filing for Q1 2026, filed 30 Apr 2026.